Home / Buffers, Chelators and Reagents / Lysis Buffer 6 (1 x 21 mL)

Lysis Buffer 6 (1 x 21 mL)

Catalog #: 895561
15 Citations 3 Reviews Datasheet
Catalog # Availability Size / Price Qty
895561
Product Details
Citations (15)
FAQs
Reviews (3)
Summary Product Datasheets

Lysis Buffer 6 (1 x 21 mL) Summary

  • Store unopened vial at 2-8 °C. Stable for up to 30 days after opening when stored at 2-8 °C.
  • For use with recommended Proteome Profiler™ Array kits. Please refer to the product-specific package insert for more information.

Kit Contents

1 vial (21 mL) of a denaturing buffered solution.

Specifications

Source
N/A
Shipping Conditions
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Storage
Store the unopened product at 2 - 8 °C. Do not use past expiration date.
Applications
ELISA

Product Datasheets

You must select a language.

x
Product Datasheet

Citations for Lysis Buffer 6 (1 x 21 mL)

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

15 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. A small-molecule PI3K? activator for cardioprotection and neuroregeneration
    Authors: Gong, GQ;Bilanges, B;Allsop, B;Masson, GR;Roberton, V;Askwith, T;Oxenford, S;Madsen, RR;Conduit, SE;Bellini, D;Fitzek, M;Collier, M;Najam, O;He, Z;Wahab, B;McLaughlin, SH;Chan, AWE;Feierberg, I;Madin, A;Morelli, D;Bhamra, A;Vinciauskaite, V;Anderson, KE;Surinova, S;Pinotsis, N;Lopez-Guadamillas, E;Wilcox, M;Hooper, A;Patel, C;Whitehead, MA;Bunney, TD;Stephens, LR;Hawkins, PT;Katan, M;Yellon, DM;Davidson, SM;Smith, DM;Phillips, JB;Angell, R;Williams, RL;Vanhaesebroeck, B;
    Nature  2023-06-01
  2. Resistance to tyrosine kinase inhibitors promotes renal cancer progression through MCPIP1 tumor-suppressor downregulation and c-Met activation
    Authors: P Marona, J Górka, O Kwapisz, J Jura, J Rys, RM Hoffman, K Miekus
    Cell Death & Disease, 2022-09-22;13(9):814.  2022-09-22
  3. PI3K/Akt pathway mediates the positive inotropic effects of insulin in Langendorff-perfused rat hearts
    Authors: Y Nakadate, A Kawakami, H Sato, T Sato, T Oguchi, K Omiya, T Matsuoka, T Schricker, T Matsukawa
    Oncogene, 2022-06-13;12(1):9793.  2022-06-13
  4. Degradation and Inhibition of Epigenetic Regulatory Protein BRD4 Exacerbate Alzheimer's Disease-Related Neuropathology in Cell Models
    Authors: S Zhang, P Bai, D Lei, Y Liang, S Zhen, G Bakiasi, H Pang, SH Choi, C Wang, RE Tanzi, C Zhang
    The Journal of Biological Chemistry, 2022-03-03;298(4):101794.  2022-03-03
  5. Genome wide CRISPR/Cas9 screen identifies the coagulation factor IX (F9) as a regulator of senescence
    Authors: P Carpintero, M Borghesan, O Eleftheria, B Pan-Castil, JA Fafián-Lab, TP Mitchell, A Yuste, M Ogrunc, TD Nightingal, M Mayan, A O'Loghlen
    Cell Death & Disease, 2022-02-19;13(2):163.  2022-02-19
  6. PARP1 Inhibitor and Trabectedin Combination Does Not Increase Tumor Mutational Burden in Advanced Sarcomas-A Preclinical and Translational Study
    Authors: Y Pignochino, G Crisafulli, G Giordano, A Merlini, E Berrino, ML Centomo, G Chiabotto, S Brusco, M Basiricò, E Maldi, A Pisacane, V Leuci, D Sangiolo, L D'Ambrosio, M Aglietta, B Kasper, A Bardelli, G Grignani
    Cancers, 2021-12-15;13(24):.  2021-12-15
  7. EphA2 Expression in Bone Sarcomas: Bioinformatic Analyses and Preclinical Characterization in Patient-Derived Models of Osteosarcoma, Ewing's Sarcoma and Chondrosarcoma
    Authors: G Giordano, A Merlini, G Ferrero, G Mesiano, E Fiorino, S Brusco, ML Centomo, V Leuci, L D'Ambrosio, M Aglietta, D Sangiolo, G Grignani, Y Pignochino
    Cells, 2021-10-26;10(11):.  2021-10-26
  8. Androgen Receptor Activation in Glioblastoma Can Be Achieved by Ligand-Independent Signaling through EGFR-A Potential Therapeutic Target
    Authors: N Zalcman, M Gutreiman, T Shahar, M Weller, I Lavon
    International Journal of Molecular Sciences, 2021-10-11;22(20):.  2021-10-11
  9. Epithelial-mesenchymal transition induced by SARS-CoV-2 required transcriptional upregulation of Snail
    Authors: YJ Lai, CH Chao, CC Liao, TA Lee, JM Hsu, WC Chou, J Wang, HC Huang, SJ Chang, YL Lin, CW Li
    American journal of cancer research, 2021-05-15;11(5):2278-2290.  2021-05-15
  10. Priming with HDAC Inhibitors Sensitizes Ovarian Cancer Cells to Treatment with Cisplatin and HSP90 Inhibitors
    Authors: AJ Rodrigues, JJ Bandolik, FK Hansen, T Kurz, A Hamacher, MU Kassack
    Int J Mol Sci, 2020-11-05;21(21):.  2020-11-05
  11. Small Extracellular Vesicles Are Key Regulators of Non-cell Autonomous Intercellular Communication in Senescence via the Interferon Protein IFITM3
    Authors: M Borghesan, J Fafián-Lab, O Eleftheria, P Carpintero, M Paez-Ribes, G Vizcay-Bar, A Swisa, D Kolodkin-G, P Ximénez-Em, R Lowe, B Martín-Mar, H Peinado, J Muñoz, RA Fleck, Y Dor, I Ben-Porath, A Vossenkamp, D Muñoz-Espi, A O'Loghlen
    Cell Rep, 2019-06-25;27(13):3956-3971.e6.  2019-06-25
  12. Targeting CREB-binding protein overrides LPS induced radioresistance in non-small cell lung cancer cell lines
    Authors: MY Gökyildiri, U Grandel, K Hattar, G Dahlem, E Schuetz, FH Leinberger, F Eberle, U Sibelius, F Grimminger, W Seeger, R Engenhart-, E Dikomey, FSB Subtil
    Oncotarget, 2018-06-22;9(48):28976-28988.  2018-06-22
  13. miR-30e* is overexpressed in prostate cancer and promotes NF-?B-mediated proliferation and tumor growth
    Authors: SM Egan, E Karasik, L Ellis, SO Gollnick
    Oncotarget, 2017-06-28;8(40):67626-67638.  2017-06-28
  14. L1 Cell Adhesion Molecule Promotes Migration and Invasion via JNK Activation in Extrahepatic Cholangiocarcinoma Cells with Activating KRAS Mutation
    Authors: H Kim, H Hwang, H Lee, HJ Hong
    Mol. Cells, 2017-05-24;40(5):363-370.  2017-05-24
  15. Glycemia and the cardioprotective effects of insulin pre-conditioning in the isolated rat heart
    Authors: Y Nakadate, H Sato, T Oguchi, T Sato, A Kawakami, T Ishiyama, T Matsukawa, T Schricker
    Cardiovasc Diabetol, 2017-04-04;16(1):43.  2017-04-04

FAQs

  1. Does Lysis Buffer 6 in the Proteome Profiler™ Array contain phosphatase and protease inhibitors?

    • Lysis Buffer 6 contains phosphatase inhibitors but not protease inhibitors. If desired, protease inhibitors can be added to the lysis buffer immediately prior to use. We recommend 10 μg/ml Aprotinin (Tocris; Catalog # 4139), 10 μg/ml Leupeptin (Tocris; Catalog # 1167), and 10 μg/ml Peptstatin (Tocris; Catalog # 1190).

View all ELISA FAQs

Reviews for Lysis Buffer 6 (1 x 21 mL)

Average Rating: 5 (Based on 3 Reviews)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%

Have you used Lysis Buffer 6 (1 x 21 mL)?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Lysis Buffer 6 (1 x 21 mL)
By Anonymous on 04/16/2021
Lysis Buffer 6 (1 x 21 mL)
By Danlee Enzler on 04/18/2018
Lysis Buffer 6 (1 x 21 mL)
By Leslie Priddy on 04/01/2018